Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy

Nanoscale ◽  
2018 ◽  
Vol 10 (44) ◽  
pp. 20851-20862 ◽  
Author(s):  
Hyunjoon Kim ◽  
Drishti Sehgal ◽  
Tamara A. Kucaba ◽  
David M. Ferguson ◽  
Thomas S. Griffith ◽  
...  
Keyword(s):  
T Cell ◽  
Cancer Immunotherapy ◽  
Cell Response ◽  
T Cell Response ◽  
Polymer Nanoparticles ◽  
Acidic Ph ◽  
Ph Responsive ◽  
Responsive Polymer ◽  
Delivery Platform

Acidic-pH responsive PLGA NPs enhance endo/lysosomal delivery of the TLR7/8 agonist and elicit a stronger anti-tumor T cell response than conventional PLGA NPs.

Robust Anti‐Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy

2020 ◽  
Vol 3 (9) ◽  
pp. 2000094 ◽  
Author(s):  
Rui Kuai ◽  
Priti B. Singh ◽  
Xiaoqi Sun ◽  
Cheng Xu ◽  
Alireza Hassani Najafabadi ◽  
...  
Keyword(s):  
T Cell ◽  
Cancer Immunotherapy ◽  
Cell Response ◽  
T Cell Response

scholarly journals Prospects of IL-2 in Cancer Immunotherapy

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Hani Choudhry ◽  
Nawal Helmi ◽  
Wesam H. Abdulaal ◽  
Mustafa Zeyadi ◽  
Mazin A. Zamzami ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Growth Factor ◽  
Adverse Effects ◽  
Cancer Immunotherapy ◽  
Cancer Patients ◽  
Cell Response ◽  
T Cell Response ◽  
Present Review ◽  
Early Use

IL-2 is a powerful immune growth factor and it plays important role in sustaining T cell response. The potential of IL-2 in expanding T cells without loss of functionality has led to its early use in cancer immunotherapy. IL-2 has been reported to induce complete and durable regressions in cancer patients but immune related adverse effects have been reported (irAE). The present review discusses the prospects of IL-2 in immunotherapy for cancer.

scholarly journals CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

2020 ◽  
Vol 8 (2) ◽  
pp. e000905 ◽  
Author(s):  
Hongfei Wang ◽  
Yixuan Sun ◽  
Xiuman Zhou ◽  
Chunxia Chen ◽  
Ling Jiao ◽  
...  
Keyword(s):  
Immune Response ◽  
Amino Acid ◽  
T Cell ◽  
Cancer Immunotherapy ◽  
Tumor Cells ◽  
Cell Response ◽  
Regulatory Protein ◽  
T Cell Response ◽  
Antitumor Effects ◽  
Pathogen Invasion

BackgroundImmunotherapy has achieved remarkable advances via a variety of strategies against tumor cells that evade immune surveillance. As important innate immune cells, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, resisting tumor cells and promoting adaptive immune response. CD47 is found to be overexpressed on tumor cells and act as a don’t eat me’ signal, which contributes to immune evasion. Macrophages mediated phagocytosis via blockade CD47/SIRPα (signal regulatory protein alpha) interaction was proved to induce effective antitumor immune response.MethodsA novel peptide pep-20, specifically targeting CD47 and blocking CD47/SIRPα interaction, was identified via high-throughput phage display library bio-panning. The capability to enhance the macrophage-mediated phagocytosis activities and antitumor effects of pep-20 were investigated. The mechanism of pep-20 to induce T-cell response was explored by ex vivo analysis and confirmed via macrophage depleting strategy. The structure-activity relationship and D-amino acid substitution of pep-20 were also studied. The antitumor effects and mechanism of a proteolysis resistant D-amino acid derivate pep-20-D12 combined with irradiation (IR) were also investigated.ResultsPep-20 showed remarkable enhancement of macrophage-mediated phagocytosis to both solid and hematologic tumor cells in vitro, and inhibited tumor growth in immune-competent tumor-bearing mice. Furthermore, pep-20 promoted macrophages to mobilize the antitumor T-cell response with minimal toxicity. Furthermore, systemic administration of the derivate pep-20-D12 showed robust synergistic antitumor efficacy in combination with IR.ConclusionIn summary, these results demonstrated that CD47/SIRPα blocking peptides, pep-20 and its derivate, could serve as promising candidates to promote macrophages-mediated phagocytosis and immune response in cancer immunotherapy.

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

2005 ◽  
Vol 7 (6) ◽  
pp. 686-695 ◽  
Author(s):  
Aude Bonehill ◽  
Carlo Heirman ◽  
Kris Thielemans
Keyword(s):  
T Cell ◽  
Cancer Immunotherapy ◽  
Cell Response ◽  
T Cell Response ◽  
Cd4 T Cell
Sign in / Sign up

Export Citation Format

Share Document